search
Back to results

Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Block (ADRIB Trial) (ADRIB)

Primary Purpose

Radius Fractures, Ulna Fractures, Hand Injuries

Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Ropivacaine
Ropivacaine + Dexmedetomidine
Sponsored by
Guangzhou First People's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Radius Fractures focused on measuring Brachial plexus block, Dexmedetomidine, Ropivacaine, ultrasound-guided nerve block, supraclavicular brachial plexus block

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Surgery: elective forearm and hand surgery under ultrasound-guided supraclavicular brachial plexus block
  • American Society of Anesthesiologist(ASA) physical status of Ⅰ to III
  • Age between 18 to 60 years old

Exclusion Criteria:

  • Having an ongoing another clinical trials
  • Taking antihypertensive drugs such as methyldopa, clonidine and other α2 receptor agonist
  • Peripheral neuropathy
  • Cerebrovascular disease
  • Psychiatric disease
  • Coagulopathies
  • Pregnant women
  • Liver and kidney dysfunction
  • Heart failure
  • Known allergy or hypersensitive reaction to dexmedetomidine or anesthetic
  • Patient refusal

Sites / Locations

  • Guangzhou First Municipal People's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Ropivacaine

Ropivacaine + Dexmedetomidine

Arm Description

After a careful aspiration, 1 to 2 mL of normal saline is injected for a distribution in and around the brachial plexus. Additional needle tip repositioning and injections may be needed when the distribution is not attained. Then the study drug (0.5% ropivacaine in a total volume of 20 mL) will be injected with additional fine adjustment of the block needle under continuous ultrasound monitoring.

After skin infiltration with 1-2 mL of lidocaine 2%, a 21-gauge 90-mm spinal needle will be inserted into the brachial plexus sheath using in-plane technique. After a careful aspiration, 1 to 2 mL of normal saline is injected for a distribution in and around the brachial plexus. Additional needle repositioning and injections may be needed when the distribution is not attained. Then the study drug (0.5% ropivacaine plus 30 microg dexmedetomidine in a total volume of 20 mL) will be injected with additional fine adjustment of the block needle under realtime ultrasound monitoring.

Outcomes

Primary Outcome Measures

Duration of analgesia
Postoperative pain using visual analog scale (VAS, 0-100, 0 = no pain, 100 = maximum imaginable pain) will be assessed. Duration of analgesia is defined by time between administration of block and the postoperative pain >3.

Secondary Outcome Measures

Blood pressure (BP)
Noninvasive arterial BP is measured at the non-operated arm. episode of hypotension (30% decrease in mean BP in relation to baseline values) and hypertension (30% increase in mean BP in relation to baseline values) will be recorded.
Heart rate (HR):
HR, bradycardia (HR < 50 beats/min), and tachycardia (HR > 100 beats/min) will be recorded at the same time as BP recording.
Peripheral oxygen saturation (SpO2)
SpO2 and hypoxemia (SpO2 <90%) will be recorded at the same time as BP recording.
Sensory block of median nerve
is defined by pinprick sensation using a 3-point scale (0-2, 0 = normal sensation, 1 = decreased pain sensation to pinprick, 2 = loss of pain sensation to pinprick) in the median nerve locations.
Sensory block of ulnar nerve
Sensory block of ulnar nerve is defined by pinprick sensation using a 3-point scale (0-2, 0 = normal sensation, 1 = decreased pain sensation to pinprick, 2 = loss of pain sensation to pinprick) in the ulnar nerve locations.
Sensory block of radial nerve
Sensory block of radial nerve is defined by pinprick sensation using a 3-point scale (0-2, 0 = normal sensation, 1 = decreased pain sensation to pinprick, 2 = loss of pain sensation to pinprick) in the radial nerve locations.
Sensory block of musculocutaneous nerve
Sensory block of musculocutaneous nerve is defined by pinprick sensation using a 3-point scale (0-2, 0 = normal sensation, 1 = decreased pain sensation to pinprick, 2 = loss of pain sensation to pinprick) in the musculocutaneous nerve locations.
Motor block of median nerve
Motor block of median nerve is defined by thumb and fifth finger pinch.
Motor block of ulnar nerve
Motor block of ulnar nerve is defined thumb and second finger pinch.
Motor block of radial nerve
Motor block of radial nerve is defined by finger abduction.
Motor block of musculocutaneous nerve
Motor block of musculocutaneous nerve is defined by flexion of the elbow.
Duration of motor block
Duration of motor block is defined as the time interval between the administration of the block and the recovery of complete motor function of the hand and forearm assessed.
Success rate of nerve block
A successful block is defined as surgery without patient discomfort and the need for supplementation of local infiltration or general anesthesia
Postoperative analgesic requirement
IV tramadol 50mg will be administered when postoperative pain >3, and be titrated up by 50 mg increments as needed for pain every 4 to 6 hours, with the maximum total dose of 250mg.
Postoperative nausea and vomiting (PONV)
The incidence of PONV will be recorded using a 4-point objective score (1 = no PONV;2 = mild nausea, no vomiting; 3 = excessive nausea or vomiting;4 = vomiting ≥2 times).
Abnormal sensation of brachial plexus
Patient's self-reported abnormal sensation of the hand and forearm.

Full Information

First Posted
December 3, 2015
Last Updated
August 10, 2016
Sponsor
Guangzhou First People's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02630290
Brief Title
Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Block (ADRIB Trial)
Acronym
ADRIB
Official Title
Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Plexus Block, a Randomized Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2016
Overall Recruitment Status
Completed
Study Start Date
December 2015 (undefined)
Primary Completion Date
June 2016 (Actual)
Study Completion Date
June 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Guangzhou First People's Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Dexmedetomidine, an alpha 2-adrenoreceptor agonist, has been found to exerts an excellent influences on the filed of perineural block. It could shorten the onset time and prolong the duration of the nerve block and improved postoperative pain. However, Dexmedetomidine-induced bradycardia or hypotension has recently attracted considerable attention because of potentially grave consequences, including sinus arrest and refractory cardiogenic shock. A low dose may help minimize cardiovascular risks associated with dexmedetomidine. However, few studies have addressed the clinical effects of low-dose dexmedetomidine as an perineural adjuvant. The present study was designed to test the hypothesis that low-dose dexmedetomidine added to ropivacaine would safely enhance the duration of analgesia without adverse effects when compared with ropivacaine alone. Investigators will conduct a single-center, prospective, randomized, triple-blind, controlled trial in patients undergoing elective forearm and hand surgery under ultrasound-guided supraclavicular brachial plexus block using either ropivacaine or ropivacaine plus low-dose dexmedetomidine. The primary outcome is self-reported duration of analgesia . Secondary outcomes include onset time and duration of motor and sensory block, total postoperative analgesics, and safety assessment (adverse effects and postoperative abnormal sensation).
Detailed Description
Dexmedetomidine, an alpha 2-adrenoreceptor agonist, has been found to exerts an excellent influences on the filed of perineural block. It could shorten the onset time and prolong the duration of the nerve block and improved postoperative pain. However, Dexmedetomidine-induced bradycardia or hypotension has recently attracted considerable attention because of potentially grave consequences, including sinus arrest and refractory cardiogenic shock. Although meta-analysis showed that perineural dexmedetomidine as a local anaesthetic adjuvant for neuraxial and peripheral nerve blocks produced reversible bradycardia in only 7% of brachial plexus block patients and no effect on the incidence of hypotension, various clinical studies reported a significant decrease in heart rate. A low dose may help minimize cardiovascular risks associated with dexmedetomidine. However, few studies have addressed the clinical effects of low-dose dexmedetomidine as an perineural adjuvant. The present study was designed to test the hypothesis that low-dose dexmedetomidine, which till today has not been reported in the literature, added to ropivacaine for brachial plexus block would safely enhance the duration of analgesia without adverse effects when compared with ropivacaine alone. Investigators will conduct a single-center, prospective, randomized, triple-blind, controlled trial in patients undergoing elective forearm and hand surgery under ultrasound-guided supraclavicular brachial plexus block using either 20 mL of 0.5% ropivacaine or 0.5% ropivacaine plus 30 microg dexmedetomidine. The primary outcome is self-reported duration of analgesia . Secondary outcomes include onset time and duration of motor and sensory block, total postoperative analgesics, and safety assessment (adverse effects including cardiovascular inhibitions and postoperative abnormal sensation). Data will be collected and analyzed in a blinded fashion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Radius Fractures, Ulna Fractures, Hand Injuries, Wrist Injuries, Forearm Injuries
Keywords
Brachial plexus block, Dexmedetomidine, Ropivacaine, ultrasound-guided nerve block, supraclavicular brachial plexus block

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ropivacaine
Arm Type
Placebo Comparator
Arm Description
After a careful aspiration, 1 to 2 mL of normal saline is injected for a distribution in and around the brachial plexus. Additional needle tip repositioning and injections may be needed when the distribution is not attained. Then the study drug (0.5% ropivacaine in a total volume of 20 mL) will be injected with additional fine adjustment of the block needle under continuous ultrasound monitoring.
Arm Title
Ropivacaine + Dexmedetomidine
Arm Type
Experimental
Arm Description
After skin infiltration with 1-2 mL of lidocaine 2%, a 21-gauge 90-mm spinal needle will be inserted into the brachial plexus sheath using in-plane technique. After a careful aspiration, 1 to 2 mL of normal saline is injected for a distribution in and around the brachial plexus. Additional needle repositioning and injections may be needed when the distribution is not attained. Then the study drug (0.5% ropivacaine plus 30 microg dexmedetomidine in a total volume of 20 mL) will be injected with additional fine adjustment of the block needle under realtime ultrasound monitoring.
Intervention Type
Drug
Intervention Name(s)
Ropivacaine
Other Intervention Name(s)
placebo
Intervention Description
Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine
Intervention Type
Drug
Intervention Name(s)
Ropivacaine + Dexmedetomidine
Other Intervention Name(s)
experimental
Intervention Description
Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine plus low-dose (30 microg) dexmedetomidine
Primary Outcome Measure Information:
Title
Duration of analgesia
Description
Postoperative pain using visual analog scale (VAS, 0-100, 0 = no pain, 100 = maximum imaginable pain) will be assessed. Duration of analgesia is defined by time between administration of block and the postoperative pain >3.
Time Frame
up to 24 hours postoperatively
Secondary Outcome Measure Information:
Title
Blood pressure (BP)
Description
Noninvasive arterial BP is measured at the non-operated arm. episode of hypotension (30% decrease in mean BP in relation to baseline values) and hypertension (30% increase in mean BP in relation to baseline values) will be recorded.
Time Frame
up to 24 hours postoperatively
Title
Heart rate (HR):
Description
HR, bradycardia (HR < 50 beats/min), and tachycardia (HR > 100 beats/min) will be recorded at the same time as BP recording.
Time Frame
up to 24 hours postoperatively
Title
Peripheral oxygen saturation (SpO2)
Description
SpO2 and hypoxemia (SpO2 <90%) will be recorded at the same time as BP recording.
Time Frame
up to 24 hours postoperatively
Title
Sensory block of median nerve
Description
is defined by pinprick sensation using a 3-point scale (0-2, 0 = normal sensation, 1 = decreased pain sensation to pinprick, 2 = loss of pain sensation to pinprick) in the median nerve locations.
Time Frame
up to 30 minutes after administration of block
Title
Sensory block of ulnar nerve
Description
Sensory block of ulnar nerve is defined by pinprick sensation using a 3-point scale (0-2, 0 = normal sensation, 1 = decreased pain sensation to pinprick, 2 = loss of pain sensation to pinprick) in the ulnar nerve locations.
Time Frame
up to 30 minutes after administration of block
Title
Sensory block of radial nerve
Description
Sensory block of radial nerve is defined by pinprick sensation using a 3-point scale (0-2, 0 = normal sensation, 1 = decreased pain sensation to pinprick, 2 = loss of pain sensation to pinprick) in the radial nerve locations.
Time Frame
up to 30 minutes after administration of block
Title
Sensory block of musculocutaneous nerve
Description
Sensory block of musculocutaneous nerve is defined by pinprick sensation using a 3-point scale (0-2, 0 = normal sensation, 1 = decreased pain sensation to pinprick, 2 = loss of pain sensation to pinprick) in the musculocutaneous nerve locations.
Time Frame
up to 30 minutes after administration of block
Title
Motor block of median nerve
Description
Motor block of median nerve is defined by thumb and fifth finger pinch.
Time Frame
up to 30 minutes after administration of block
Title
Motor block of ulnar nerve
Description
Motor block of ulnar nerve is defined thumb and second finger pinch.
Time Frame
up to 30 minutes after administration of block
Title
Motor block of radial nerve
Description
Motor block of radial nerve is defined by finger abduction.
Time Frame
up to 30 minutes after administration of block
Title
Motor block of musculocutaneous nerve
Description
Motor block of musculocutaneous nerve is defined by flexion of the elbow.
Time Frame
up to 30 minutes after administration of block
Title
Duration of motor block
Description
Duration of motor block is defined as the time interval between the administration of the block and the recovery of complete motor function of the hand and forearm assessed.
Time Frame
up to 24 hours postoperatively
Title
Success rate of nerve block
Description
A successful block is defined as surgery without patient discomfort and the need for supplementation of local infiltration or general anesthesia
Time Frame
30 minutes after administration of block
Title
Postoperative analgesic requirement
Description
IV tramadol 50mg will be administered when postoperative pain >3, and be titrated up by 50 mg increments as needed for pain every 4 to 6 hours, with the maximum total dose of 250mg.
Time Frame
up to 24 hours postoperatively
Title
Postoperative nausea and vomiting (PONV)
Description
The incidence of PONV will be recorded using a 4-point objective score (1 = no PONV;2 = mild nausea, no vomiting; 3 = excessive nausea or vomiting;4 = vomiting ≥2 times).
Time Frame
up to 24 hours postoperatively
Title
Abnormal sensation of brachial plexus
Description
Patient's self-reported abnormal sensation of the hand and forearm.
Time Frame
Day 1
Other Pre-specified Outcome Measures:
Title
The block performance time
Description
Time elapses from probe positioning to the end of local anesthetic injection.
Time Frame
1 day
Title
The number of block performance attempts
Description
Number of block performance attempts
Time Frame
1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Surgery: elective forearm and hand surgery under ultrasound-guided supraclavicular brachial plexus block American Society of Anesthesiologist(ASA) physical status of Ⅰ to III Age between 18 to 60 years old Exclusion Criteria: Having an ongoing another clinical trials Taking antihypertensive drugs such as methyldopa, clonidine and other α2 receptor agonist Peripheral neuropathy Cerebrovascular disease Psychiatric disease Coagulopathies Pregnant women Liver and kidney dysfunction Heart failure Known allergy or hypersensitive reaction to dexmedetomidine or anesthetic Patient refusal
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xiangcai Ruan, MD, PhD
Organizational Affiliation
Guangzhou First People's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Guangzhou First Municipal People's Hospital
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
020
Country
China

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
24671181
Citation
Wu HH, Wang HT, Jin JJ, Cui GB, Zhou KC, Chen Y, Chen GZ, Dong YL, Wang W. Does dexmedetomidine as a neuraxial adjuvant facilitate better anesthesia and analgesia? A systematic review and meta-analysis. PLoS One. 2014 Mar 26;9(3):e93114. doi: 10.1371/journal.pone.0093114. eCollection 2014.
Results Reference
result
PubMed Identifier
23161360
Citation
Marhofer D, Kettner SC, Marhofer P, Pils S, Weber M, Zeitlinger M. Dexmedetomidine as an adjuvant to ropivacaine prolongs peripheral nerve block: a volunteer study. Br J Anaesth. 2013 Mar;110(3):438-42. doi: 10.1093/bja/aes400. Epub 2012 Nov 15.
Results Reference
result
PubMed Identifier
23587874
Citation
Abdallah FW, Brull R. Facilitatory effects of perineural dexmedetomidine on neuraxial and peripheral nerve block: a systematic review and meta-analysis. Br J Anaesth. 2013 Jun;110(6):915-25. doi: 10.1093/bja/aet066. Epub 2013 Apr 15.
Results Reference
result
PubMed Identifier
20889939
Citation
Esmaoglu A, Yegenoglu F, Akin A, Turk CY. Dexmedetomidine added to levobupivacaine prolongs axillary brachial plexus block. Anesth Analg. 2010 Dec;111(6):1548-51. doi: 10.1213/ANE.0b013e3181fa3095. Epub 2010 Oct 1.
Results Reference
result
PubMed Identifier
35931989
Citation
Liu W, Guo J, Zheng J, Zheng B, Ruan X; Addition of Dexmedetomidine to Ropivacaine-Induced supraclavicular Block (ADRIB) investigator. Low-dose dexmedetomidine as a perineural adjuvant for postoperative analgesia: a randomized controlled trial. BMC Anesthesiol. 2022 Aug 5;22(1):249. doi: 10.1186/s12871-022-01791-6.
Results Reference
derived

Learn more about this trial

Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Block (ADRIB Trial)

We'll reach out to this number within 24 hrs